Advice
following a full submission:
aclidinium/formoterol fumarate dihydrate (Duaklir Genuair®) is accepted for use within NHS Scotland.
Indication under review: Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
In two 24-week comparator- and placebo-controlled phase III studies, treatment with aclidinium/formoterol 340/12 microgram resulted in statistically significant improvements in FEV1 % predicted pre-dose (versus a LABA) and post-dose (versus a LAMA).
Download detailed advice199KB (PDF)
Medicine details
- Medicine name:
- aclidinium/formoterol fumarate dihydrate (Duaklir Genuair)
- SMC ID:
- 1034/15
- Indication:
- Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
- Pharmaceutical company
- Almirall Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 April 2015